This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.
Please go to www.ahrq.gov for current information.
Table 4. Summary of Patient Survival in Studies of First-line Treatment With EGFR-TK Inhibitors Combined With Cytotoxic Agents for patients With Advanced NSCLC
| Study ID |
Diagnosis
(no. of patients) |
Sub-groups (dosage in mg/day) |
Survival from Start of Treatment |
Progression-free Survival |
| Median (months) |
1-year
(%) |
HR (95% CI)
[p-value] |
Median TTP
(months) |
1-year
(%) |
HR (95% CI)
[p-value]
|
|
Herbst, et al., 20046
|
NSCLC
(345)
(345)
(347)
|
Placebo
Gefitinib 250
Gefitinib 500
|
9.9
9.8
8.7
|
42
41
37
|
NS
|
5.0
5.3
4.6
|
- -
- -
- -
|
NS
|
|
Giaccone, et al., 20047
|
NSCLC
(363)
(365)
(365)
|
Placebo
Gefitinib
250
Gefitinib
500
|
10.0
9.9
9.9
|
44
41
43
|
NS
|
6.0
5.8
5.5
|
- -
- -
- -
|
NS
|
|
Miller, et al., 20048
|
NSCLC
(533)
(526)
|
Placebo
Erlotinib 150
|
10.5
10.6
|
- -
- -
|
0.995
[p = 0.95; NS]
|
4.9
5.1
|
- -
- -
|
0.937
[p = 0.36, NS]
|
|
Gatzemeier, et al., 20049
|
NSCLC
(~575)
(~575)
|
Placebo
Erlotinib 150
|
10.2
9.9
|
- -
- -
|
NS
|
5.9
5.5
|
- -
- -
|
NS
|
Abbreviations: CI = confidence interval; EGFR-TK = epidermal growth factor receptor tyrosine kinase; HR = hazard ratio; no. = number; NS = not statistically significant; NSCLC = non-small cell lung cancer; TTP = time to progression
Return to Document
540 Gaither Road Rockville, MD 20850